Zenas BioPharma, Inc. ZBIO

US Biotechnology

$28.88 ▲ +1.09% (+$0.31)

🔥 High Short Interest

Open $27.82

Prev Close $28.57

Day Range $27.82 – $29.90

52W Range $13.50 – $44.60

Market Cap $1.85B

Beta 0.70

EPS (TTM) $-9.40

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2024-09-13
Shares Out.	65,180,000
Website	zenasbio.com/ ↗
Phone	13026587581
Employees	167
Revenue	$1.0M
Gross Profit	$1.0M
Net Income	-$111.5M
Free Cash Flow	-$226.0M
Total Assets	$701.7M
Total Liabilities	$454.6M
Equity	$247.1M

About Zenas BioPharma, Inc.

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

Zenas BioPharma, Inc. is a publicly traded company under the ticker symbol ZBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.